China bears a substantial disease burden of chronic hepatitis B (CHB). Under current clinical management regimens for CHB,achieving functional cure (also termed clinical cure) is the core goal for the treatment of patients meeting treatment indications. To achieve the goal of functional cure,drug regulatory authorities in China and globally have successively issued technical criteria to provide guidance for the overall design and scientific evaluation of clinical trials for innovative drugs. However,the rapid development in scientific research,clinical practice,and new drug research and development in this field has brought new challenges,especially those concerning the assessment of the clinical value of investigational drugs. This article reviews the current status of clinical research and development of new drugs for achieving the functional cure of CHB worldwide,analyzes the characteristics of available clinical trial data,and focuses on key aspects of pivotal clinical trials for CHB functional cure drugs,including target populations (baseline HBsAg level),HBsAg seroclearance response,HBsAg seroreversion after drug withdrawal,and clinically meaningful target threshold of functional cure response rate,in order to provide a reference for further refinement of related technical criteria.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |